We recently published 11 Best Cancer Stocks to Buy Right Now. Incyte Corporation stands fourth on our list. Incyte Corporation (NASDAQ:INCY) is a biopharmaceutical company focused on cancer and ...

Looking for a stock that has been consistently beating earnings estimates and might be well positioned to keep the streak alive in its next quarterly report? Incyte (INCY), which belongs to the Zacks ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

Looking ahead to 2030, our model projects INCY could trade at an average price of $200.77, with a potential range between $150.58 and $250.97. This represents a potential 86.2% return from today's ...

Shares of Incyte INCY were on the upward trajectory in the past three months. The stock has risen 19.6% in this time frame compared with the industry’s growth of 8.9%. Last week, Incyte announced that ...

Fintel reports that on May 22, 2026, Bernstein initiated coverage of Incyte (NasdaqGS:INCY) with a Market Perform recommendation. Analyst Price Forecast Suggests 13.67% Upside As of May 13, 2026, the ...

In this article, we will be taking a look at the 11 Best Performing Biotech Stocks So Far in 2025. Incyte Corporation is one of them. Incyte Corporation (NASDAQ:INCY), a global biopharmaceutical ...